The UK Medicines and Healthcare products Regulatory Agency (MHRA) has permitted Sorrento Therapeutics to commence a Phase II efficacy trial of its product candidate, COVI-DROPS, to treat Covid-19 in the outpatient setting.
Administered intranasally, COVI-DROPS contain a neutralising antibody that potentially works against the original SARS-CoV-2 virus and the UK/Alpha and India/Delta variants.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Sorrento submitted the Phase II trial application through a rolling submission approach and received MHRA clearance in under a month from its first filing with the regulatory agency.
The submission was backed by the safety data from a US study in healthy subjects, where the product candidate demonstrated a safety profile comparable to placebo with doses of up to 60mg.
Furthermore, no serious adverse effects or dose-limiting toxicities were noted in the study, with all adverse effects being mild.
The company noted that the maximum tolerated dose was not reached.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe large, randomised, double-blind, Phase II efficacy trial will enrol 350 asymptomatic or mildly symptomatic outpatients with Covid-19.
Participants will be categorised in a 2:2:1 ratio to receive either a 10mg or 20mg dose of the product or placebo.
Sorrento noted that the latest trial will support a Phase II study in the US and a separate trial in Mexico.
The Phase II efficacy trial results in the UK will be merged with the data from the US and Mexico studies.
If COVI-DROPS is found to be safe and effective against SARS-CoV-2, Sorrento plans to seek emergency use authorisation in the US, India, UK, Mexico, EU, and other regions.
In a separate development, the US Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application of Vicore Pharma’s lead candidate, C21, for treating Covid-19.
The active IND aids in commencing Phase III ATTRACT-3 trial of the angiotensin II type 2 receptor (AT2R) agonist at various centres in the US.
